BEVERLY HILLS, Calif., April 4, 2016 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that is has retained the services of an Asian Contract Research Organization ("CRO"), CMIC ASIA-PACIFIC, PTE. LTD. ("CMIC"), to run Rich's upcoming Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. CMIC is considered to be one of Asia's top CRO's for running clinical oncology studies.
"We are very pleased to have retained the services of a well respected and internationally recognized CRO which specializes in managing clinical studies," said Ben Chang, Chief Executive Officer of Rich. "After carefully evaluating many competing organizations, we have chosen this CRO based on their extensive experience in managing global clinical trials of medicines."
About CMIC ASIA-PACIFIC, PTE. LTD.
CMIC ASIA-PACIFIC, PTE. LTD. is one of the leading Asian pharmaceutical service providers with Headquarters in Japan （CMIC HOLDINGS Co., Ltd. in Japan, and has operations in China, Korea, Taiwan, Hong Kong, Singapore, Malaysia, Thailand, Vietnam and other Asian countries. CMIC ASIA-PACIFIC, PTE. LTD. provides consulting services, clinical development services, post marketing research, commercialization and industry expertise from early phase studies to late phase studies to support global and local clinical development. CMIC ASIA-PACIFIC, PTE. LTD. also manages investigator-initiated trials, observational studies and registry studies. Find out more at http://www.cmic-apac.com
This press release contains certain "forward-looking statements" which are statements that are not purely historical, and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate. Investors should refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC (at www.sec.gov).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-retains-contract-research-organization-cmic-to-manage-upcoming-phase-12-clinical-trial-for-its-acute-myelocytic-leukemia-aml-and-myelodysplastic-syndrome-mds-drug-in-thailand-300245150.html
SOURCE Rich Pharmaceuticals, Inc.